AKT1 and acute myeloid leukemia: For instance, while many studies focus on mTOR/AKT/PI3K hyperactivation in specific AML subtypes or under certain microenvironmental conditions, our findings may reflect distinct regulatory dynamics influenced by miR‐100 and miR‐101 expression.